Decitabine

目录号:S1200 别名: Deoxycytidine

Decitabine Chemical Structure

Molecular Weight(MW): 228.21

Decitabine是DNA甲基转移酶抑制剂,整合进入DNA、导致DNA低甲基化,并使DNA复制停滞在intra-S-phase。Decitabine被用于治疗骨髓增生异常综合征(MDS)。

规格 价格 库存 购买数量  
RMB 1269.11 现货
RMB 732.42 现货
RMB 1419.77 现货
RMB 2621.82 现货
RMB 4679.47 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用该产品的3个实验数据:

  • (A) and (B) SW1116 and LOVO cells were plated, treated for 48 h with decitabine (DAC) and gefitinib (GEF) either alone or in combination, and the expression levels of AKT, mTOR, S6K, and phosphorylation were determined by Western blot analysis as described under Methods. Expression of β-actin served as a loading control. The data are representative of three independent experiments.

    PLoS One 2014 9(5), e97719. Decitabine purchased from Selleck.

    (A) and (B) SW1116 and LOVO cells were cultured in control conditions (DMSO) or in the presence of the indicated concentrations of decitabine (DAC) and gefitinib (GEF), alone or in combination, for 48 h. And then cells were stained with Annexin V-FITC and propidium iodide (PI) and analyzed by flow cytometry. This experiment was done in triplicate and representative diagrams of Annexin V-FITC assays are shown.

    PLoS One 2014 9(5), e97719. Decitabine purchased from Selleck.

  • Leuk Res 2014 38(3), 402-10. Decitabine purchased from Selleck.

产品安全说明书

DNA Methyltransferase抑制剂选择性比较

生物活性

产品描述 Decitabine是DNA甲基转移酶抑制剂,整合进入DNA、导致DNA低甲基化,并使DNA复制停滞在intra-S-phase。Decitabine被用于治疗骨髓增生异常综合征(MDS)。
特性 Decitabine 是DNA甲基化的有效抑制剂。
靶点
DNA methylation [1]
(HL-60, KG1a cells)
体外研究

Decitabine 有效抑制DNA 合成,这种作用存在剂量依赖性,作用于HL-60和 KG1a 白血病细胞时,IC50分别为 100 ng/mL 和1 ng/mL。Decitabine 抑制细胞生长,这种作用存在剂量和时间依赖性,处理HL-60和KG1a白血病细胞72小时和96小时,IC50分别约为100 ng/mL 和 10 ng/mL。[1] 最新研究显示Decitabine作用于间变性大细胞淋巴瘤(ALCL),具有抗增殖和促凋亡活性,且抑制KARPAS-299细胞中[3H]胸甘的摄取,EC50 为0.49 μM。[2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Eca109 MoHaSpVv[3Srb36gRZN{[Xl? MojwNE42yqEQvF2= Mn3uNlQhcA>? MXH3ZZRmeg>? NYHpVZlZdW:mdXzheIV{KHSqZTDn[Y5mKGW6cILld5Nqd25ib3[gUWFITS2DIH3lcYJmenN? NUfu[ll5OjVzMkOwPFI>
Eca109 NYXUfFlkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4jtTVAvPS9{LkWvOUDPxE1? NHLlUYMzPC92OD:3NkBp NGrpd5B4[XSnch?= MWfpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCkb4ToJIRwe2VvIHHu[EB1cW2nLTDk[ZBmdmSnboSgcYFvdmW{ MYKyOVEzOzB6Mh?=
Eca109 MoToSpVv[3Srb36gRZN{[Xl? MYiwMlXDqM7:TR?= M2XzPFYwOTJxMkSgbC=> MlzUe4F1\XJ? MoHRbY5pcWKrdIOgZ4VtdCCvaXfyZZRqd28EoB?= MkfFNlUyOjNyOEK=
Eca109 MWPGeY5kfGmxbjDBd5NigQ>? MmHqNE42yqEQvF2= NXrVPJhnOjRiaB?= MYT3ZZRmeg>? NVi5OFdRcW6qaXLpeJMh[2WubDDpcpZie2mxbh?= NITHWlYzPTF{M{C4Ni=>
Eca109 NXHvVG5VT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXzMPXM{OC53wrFOwG0> NYDYNVMxOjRiaB?= NH3kSpF4[XSnch?= M2T5Z4lv\HWlZYOgS|IwVSCjcoLld5QhcW5idHjlJINmdGxiY4njcIU> MmHINlUyOjNyOEK=
Eca109 NWeyTYpDTnWwY4Tpc44hSXO|YYm= NGH0NHExNjVxMTFOwG0> Mk\GNlQhcA>? M3K4b5difGW{ M2j2O4Rm[3KnYYPld{BmgHC{ZYPzbY9vKG:oIF7GMe67SjJiYX7kJG1OWDJ? Ml3kNlUyOjNyOEK=
SW1116  NHW3[INIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW\3PWZ7OC53L{GvNk82KM7:TR?= MlnaOFghcA>? MoPvSG1UVw>? M3rsboVvcGGwY3XzJJRp\SCJZX\peIlvcWJiaX7keYNm\CClZXzsJIlvcGmkaYTpc44> MnnFNlQ5PzR{OE[=
LOVO NYD6V5BqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlXFNE42NzFxMj:1JO69VQ>? NUnWeGVHPDhiaB?= M1XyW2ROW09? MlO3[Y5p[W6lZYOgeIhmKEenZnn0bY5q[iCrbnT1Z4VlKGOnbHygbY5pcWKrdHnvci=> NGrGUnUzPDh5NEK4Oi=>
SW1116  MojVSpVv[3Srb36gRZN{[Xl? MnnHNVAh|ryP NEOyTYc1QCCq NXLSbIV4TE2VTx?= MUTpcoNz\WG|ZYOgeIhmKGWoZnXjeIl3\SCjdDDpcohq[mm2aX7nJGFMXCCjbnSgcXRQWiC|aXfuZYxqdmdicHH0bJdigXNiY3;tZolv\WRid3n0bEBo\W[rdHnubYI> M4G2V|I1QDd2Mki2
LOVO Mn\1SpVv[3Srb36gRZN{[Xl? Mk[yNVAh|ryP MYS0PEBp MV7EUXNQ M1jYNolv[3KnYYPld{B1cGViZX\m[YN1cX[nIHH0JIlvcGmkaYTpcochSUuWIHHu[EBuXE:UIIPp[45idGmwZzDwZZRpf2G7czDjc41jcW6nZDD3bZRpKGenZnn0bY5q[g>? M1T1VVI1QDd2Mki2
SW1116  M2XvdWFxd3C2b4Ppd{BCe3OjeR?= MnPKNVAh|ryP M{G1U|Q5KGh? MlKySG1UVw>? NGrwbodmdmijbnPld{BI\W[rdHnubYIucW6mdXPl[EBieG:ydH;zbZM> MVqyOFg4PDJ6Nh?=
LOVO M361NmFxd3C2b4Ppd{BCe3OjeR?= NF32TXIyOCEQvF2= NVLxUWJXPDhiaB?= M2DqbWROW09? NYjjR3Jy\W6qYX7j[ZMhT2WoaYTpcoljNWmwZIXj[YQh[XCxcITvd4l{ MkPBNlQ5PzR{OE[=
RPMI-8226 MV\BdI9xfG:|aYOgRZN{[Xl? NGXmbocyNzJizszN NIr4Xok1QC95Mj:5OkBp MV3EUXNQ M2PmPIlv\HWlZYOgZ4VtdCCjcH;weI9{cXN? MoPINlQ5OzNzMEi=
OPM-2  MXzBdI9xfG:|aYOgRZN{[Xl? M{\GelEwOiEQvF2= M{fOU|czNzl4L{GyNEBp NWjrZlRETE2VTx?= MXHpcoR2[2W|IHPlcIwh[XCxcITvd4l{ NX7HNWVGOjR6M{OxNFg>
JJN3  MVTBdI9xfG:|aYOgRZN{[Xl? MmTFNE42NzFizszN M4HkR|I1NzR6IHi= NX\rT2R2TE2VTx?= NHSx[5RqdmS3Y3XzJINmdGxiYYDvdJRwe2m| NFvZWlUzPDh|M{GwPC=>
NCI-H929  Mk\uRZBweHSxc3nzJGF{e2G7 NYHuXmZ{OS9{IN88US=> M1rzVFczNzl4L{GyNEBp MYnEUXNQ NVv3SJFTcW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= NVvQZoJjOjR6M{OxNFg>
RPMI-8226 NYLKZlRJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH;XOVMyNzJizszN NIPtR5AzPC92OD:3NkBp NVXRe|FJTE2VTx?= NV3FfY02[W[oZXP0d{Bk\WyuIHP5Z4xmKHC{b3fy[ZN{cW:wIH7l[4F1cX[nbIm= MUSyOFg{OzFyOB?=
OPM-2  MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoDKNU8zKM7:TR?= NYm5VXdCOjRxNEivO|IhcA>? MlXaSG1UVw>? NXrROHJV[W[oZXP0d{Bk\WyuIHP5Z4xmKHC{b3fy[ZN{cW:wIH7l[4F1cX[nbIm= M1jneFI1QDN|MUC4
JJN3  M1fwOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVGwMlUwOSEQvF2= MU[yOE81QC95MjDo MVLEUXNQ NInUWpli\m[nY4TzJINmdGxiY4njcIUheHKxZ4Lld5Nqd25ibnXnZZRqfmWueR?= NIXBT3ozPDh|M{GwPC=>
NCI-H929  M2TqfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGLiV44yNzJizszN M3\uR|I1NzR6L{eyJIg> MYHEUXNQ MX7h[oZm[3S|IHPlcIwh[3mlbHWgdJJw\3Knc4Ppc44hdmWpYYTpeoVtgQ>? NVf0ToNiOjR6M{OxNFg>
HeLa MWDLbY5ie2ViQYPzZZk> MVfLbV0yODBy4pETOVAxOCEQvF2g[o9zKGiHTmSx MVWyOFc5ODB7OB?=
HeLa M1HLXGtqdmG|ZTDBd5NigQ>? NHPzVFRMcT13Lk[gxtEhOC53IN88UUBnd3JiaFXOWFI> NFXieHQzPDd6MEC5PC=>
HeLa M2\SZWtqdmG|ZTDBd5NigQ>? NVvzSYh5U2l;MkGuOkDDuSB|LkCg{txOKG[xcjDoR25VOQ>? NGixUXIzPDd6MEC5PC=>
HeLa MX3LbY5ie2ViQYPzZZk> NGfsSIxMcT1zND60JOKyKDRwNjFOwG0h\m:{IHjDUnQ{ NIfjVJMzPDd6MEC5PC=>
NB4 MWDGeY5kfGmxbjDBd5NigQ>? MV:yMlUwPS95LkWvNVAh|ryP M2XCZVI1KGh? Mlr4SG1UVw>? MkXmbY5kemWjc3XhJJRp\SCneIDy[ZN{cW:wIH;mJJBz\WO3coPvdkBucVJvMUK1ZS=> NFXySXEzPDR6NEi3NC=>
CD4+ CD25− T  NHm0cG5HfW6ldHnvckBCe3OjeR?= NHHPfoYyNzVizszN NHK1Um1z\WS3Y3XTJIdtd2KjbDDEUmEhdWW2aInsZZRqd25? NXjXOIlDOjR2N{[zOlA>
BV-173 M1L3OGFxd3C2b4Ppd{BCe3OjeR?= MofLNE4zPS9yLkWvNE44PS9zIN88US=> Mmr2OFgwPzJxOU[gbC=> NHr4RXjDqFCEUx?= M1S4NIlv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZo91cCCmb4PlMUBidmRidHnt[U0h\GWyZX7k[Y51KG2jbn7ldi=> M3njNFI1PDJ|NkGz
ML-1 NE[yNJBCeG:ydH;zbZMhSXO|YYm= NXy5UFdwOC5{NT:wMlUwOC55NT:xJO69VQ>? NG\tWpI1QC95Mj:5OkBp NWOyUlMzyqCSQmO= MUTpcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHLveIgh\G:|ZT2gZY5lKHSrbXWtJIRmeGWwZHXueEBu[W6wZYK= M2rwXVI1PDJ|NkGz
HL-60 MUDBdI9xfG:|aYOgRZN{[Xl? M3fsbVAvOjVxMD61M|AvPzVxMTFOwG0> NYS5TGE4PDhxN{KvPVYhcA>? M2fWVuKhWEKV NX24RY9ncW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBjd3SqIHTvd4UuKGGwZDD0bY1mNSCmZYDlcoRmdnRibXHucoVz NHSwNmIzPDR{M{[xNy=>
KG-1a NXfB[4VuSXCxcITvd4l{KEG|c3H5 M1\MclAvOjVxMD61M|AvPzVxMTFOwG0> MVm0PE84Oi97NjDo NF;Zfm/DqFCEUx?= M3HVPIlv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZo91cCCmb4PlMUBidmRidHnt[U0h\GWyZX7k[Y51KG2jbn7ldi=> NGXuSVEzPDR{M{[xNy=>
BV-173 NYL4bndkTnWwY4Tpc44hSXO|YYm= NXOzdZNEOjVyL{WwNI5O MXq0PEBp NHHXd3jDqFCEUx?= MoPIbY5lfWOnczDk[YxigWWmIHHu[EB{fXO2YXnu[YQhWk:VIHnuZ5Jm[XOn MXSyOFQzOzZzMx?=
CEM NEXNSG5HfW6ldHnvckBCe3OjeR?= MVyyOVAwPTBybl2= M2LqeVQ5KGh? NGnsS4HDqFCEUx?= MUfpcoR2[2W|IHTlcIF6\WRiYX7kJJN2e3SjaX7l[EBTV1NiaX7jdoVie2V? M4iyfFI1PDJ|NkGz
HL-60 MmrNSpVv[3Srb36gRZN{[Xl? NYDW[4U5OjVyL{WwNI5O M3H4XlQ5KGh? M1vmT:KhWEKV MnHrbY5lfWOnczDk[YxigWWmIHHu[EB{fXO2YXnu[YQhWk:VIHnuZ5Jm[XOn Mk\YNlQ1OjN4MUO=
ML-1 NEDUSoZHfW6ldHnvckBCe3OjeR?= MXeyOVAwPTBybl2= MVu0PEBp M{nCWOKhWEKV MWTpcoR2[2W|IHTlcIF6\WRiYX7kJJN2e3SjaX7l[EBTV1NiaX7jdoVie2V? M16xWVI1PDJ|NkGz
DLD-1 NGfCOGVHfW6ldHnvckBCe3OjeR?= NUfucY9NOjVyL{WwNI5O NETuVoQ1QCCq MYVCpHBDWw>? NUTSN5JP\G9ibn;0JIlv\HWlZYOg[IVt[XmnZDDhcoQhe3W|dHHpcoVlKFKRUzDpcoNz\WG|ZR?= NFTnfWgzPDR{M{[xNy=>
HCT-116 NXi1dno6TnWwY4Tpc44hSXO|YYm= MYWyOVAwPTBybl2= NXnPRW9oPDhiaB?= NGLCOmzDqFCEUx?= NGD2codldyCwb4SgbY5lfWOnczDk[YxigWWmIHHu[EB{fXO2YXnu[YQhWk:VIHnuZ5Jm[XOn NV\Dd3ltOjR2MkO2NVM>
U937-A/E-9/14/18  MonjRZBweHSxc3nzJGF{e2G7 NHjMd3IxNjBzL{CuNU8yNzFyIN88US=> NWXoNG9SPDhiaB?= MkTnbY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MkjmNlQ{ODB2NU[=
HT29 NW\0c2hoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1T3W|czKGh? MWXJR|UxRTF2MEFCtVE4QSEQvF2= Mlu2NlQyPzJyNkG=
SW48 NXPjW|hYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmS4O|IhcA>? MY\JR|UxRTF3LkNCtVYvOiEQvF2= MYWyOFE4OjB4MR?=
HCT116 MoLZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2i5T|czKGh? MYfJR|UxRTFwN9MxNE41KM7:TR?= M4f6dVI1OTd{ME[x
HepG2 MlrKSpVv[3Srb36gRZN{[Xl? MWewMlUwOSEQvF2= M1v4N|I1KGh? M4Pp[2ROW09? MUX1dE1z\We3bHH0[YQhfGinIILlcIF1cX[nIF;DWG4zKG2UTlGgZY5lKHC{b4TlbY4h\XiycnXzd4lwdg>? M3L5V|I1OTR4OEe0
LS174T NX25VHdTTnWwY4Tpc44hSXO|YYm= MX:wMlUwOSEQvF2= M330cVI1KGh? NHH2TItFVVOR M1v6OIxm[WRidH:gZY4hcW6lcnXhd4Uhd2ZiT1PUUlIhdGW4ZXzz NYPaXI9tOjRzNE[4O|Q>
HepG2 MYXBdI9xfG:|aYOgRZN{[Xl? MkjvNU8yOC9zMECg{txO MlTTO{Bl M3LPdGROW09? NXG4TXVUcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NUnUSYtQOjRzNE[4O|Q>
LS174T NWi2[GVMSXCxcITvd4l{KEG|c3H5 Mk\yNU8yOC9zMECg{txO MUK3JIQ> MYHEUXNQ NEDXeoJqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ MorONlQyPDZ6N{S=
QBC-939 MY\BdI9xfG:|aYOgRZN{[Xl? NYXQVWNiOS9zMD:xNFAh|ryP MmnQO{Bl NX3Ye3RvTE2VTx?= NFPjRYdqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ MVOyOFE1Pjh5NB?=
U251 MYDBdI9xfG:|aYOgRZN{[Xl? M2\hXVEwOTBxMUCwJO69VQ>? MorzO{Bl MlGwSG1UVw>? M2PMWolv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NXTDU|ZNOjRzNE[4O|Q>
HL-60 NYTPO5Q6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1fyOVEh|ryP MnjwOFghcA>? Ml\RbY5kemWjc3XzJGczNXCqYYPlJINmdGxiZoLhZ5Rqd25? MXKyOFAxODN{NB?=
MDA‑MB‑453 MX3GeY5kfGmxbjDBd5NigQ>? NICzZ3YxNjJxMTFOwG0> NFXTeZI4OiCq NIXPOm9k[XW|ZYOgdoUu\XiycnXzd4lwdiCxZjDjcIF2\GmwwrCxxsA> M2fsS|I{QDR2MkK4
HCC1569 M1GxWWZ2dmO2aX;uJGF{e2G7 NW\oXHc{OC5{L{Gg{txO MX:3NkBp M2nmSINifXOnczDy[U1mgHC{ZYPzbY9vKG:oIHPsZZVlcW8EoEJCpC=> MoqxNlM5PDR{Mki=
BT‑474 NGLJRYhHfW6ldHnvckBCe3OjeR?= NXfpcVFsOC5{L{Gg{txO NVGyS3dMPzJiaB?= NH\z[ldk[XW|ZYOgdoUu\XiycnXzd4lwdiCxZjDjcIF2\GmwwrCxxsA> M4LrW|I{QDR2MkK4
AGS NF7UbZFCeG:ydH;zbZMhSXO|YYm= MXW1M|ExNzJyL{WwJO69VQ>? NH\pTZc1QMLiaNMg M2Xsb2ROW09? MWrpcohq[mm2czD0bIUh[2WubDD2bYFjcWyrdIpCpC=> MojqNlM2QDJ5OES=
A549 M3XUfmFxd3C2b4Ppd{BCe3OjeR?= NETaTHg2NzFyL{KwM|UxKM7:TR?= M1jwT|Q5yqCqwrC= MX;EUXNQ MX;pcohq[mm2czD0bIUh[2WubDD2bYFjcWyrdIpCpC=> NFS3T5ozOzV6Mke4OC=>
AGS  MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV61M|ExNzJyL{WwJO69VQ>? NYH6dXlIPDkEoHlCpC=> NH\hPZdFVVOR NUm3NI41cW6mdXPld{BIOi:PIIDoZZNmKGG{cnXzeOKh MYGyN|U5Ojd6NB?=
Kasumi-1 MmLURZBweHSxc3nzJGF{e2G7 NW\XbXpIOC53IN88US=> NVvXdXNsPDkEoHlCpC=> M1;obYRm[3KnYYPld{B1cGViY3XscEB3cWGkaXzpeJkh[29vdILlZZRm\CC5aYToJHRnNU6SLYPj M{DsN|I{PDl|M{S4
OCI-AML3 NU[0PFhSSXCxcITvd4l{KEG|c3H5 M3u3WlIvPSEQvF2= MXq0POKhcMLi NVLHWFYz\GWlcnXhd4V{KHSqZTDj[YxtKH[rYXLpcIl1gSClbz30doVifGWmIIfpeIghXGZvTmCtd4M> MYOyN|Q6OzN2OB?=
MV4-11 MmDhRZBweHSxc3nzJGF{e2G7 MV2yMlUh|ryP M4S5NFQ5yqCqwrC= MXnk[YNz\WG|ZYOgeIhmKGOnbHygeoli[mmuaYT5JINwNXS{ZXH0[YQhf2m2aDDU[k1PWC2|Yx?= M17WS|I{PDl|M{S4
NK  NVy5XWgyS3m2b4TvfIl1gSCDc4PhfS=> NWnC[2NUOC5yMj2yNEDPxE1? MlzBOUBl NWjOTotj\GWlcnXhd4V{KHSqZTDjfZRwdHm2aXOgZYN1cX[rdImgc4YhVktiY3XscJMh[XRiaX70[ZJu\WSrYYTlJINwdmOnboTyZZRqd26|IILld5VtfGmwZzDpckBiKFVvc3jhdIVlKGSxc3ZihLNz\XOyb37z[UBkfXK4ZR?= NG\Bd4MzOzN{OEC4PC=>
NK  MnHaRZBweHSxc3nzJGF{e2G7 NYjTTZJiOC5yMj2yNEDPxE1? NGTpb2M2KGR? MlzN[IVkemWjc3WgUmsh[2WubDDwdo9tcW[ncnH0bY9vKGGwZDD2bYFjcWyrdImgZZMhfGinIHPvcoNmdnS{YYTpc44hcW6lcnXhd4Vl NGXzXIczOzN{OEC4PC=>
NK  M1:2V2Z2dmO2aX;uJGF{e2G7 NE\nTIoxNjBzLUKwJO69VQ>? MnTxOUBl NHLmN4Rk[XW|ZYOgbJlxd22ndHj5cIF1cW:wIH;mJG5MKGOnbHzzJIlvKGFiZH;z[gKBm3Knc4DvcpNm MVOyN|MzQDB6OB?=
MOLT4/DNR MlP1SpVv[3Srb36gRZN{[Xl? M{\aZVUh|ryP NXrtTW9{PCCm MlXWdoVlfWOnczDBRmNDOSCvUl7BJIV5eHKnc4Ppc44> M3\lTlI{ODZyNUew
Jurkat/DOX NHK5eVRHfW6ldHnvckBCe3OjeR?= M2XYNlUh|ryP MVu0JIQ> NHfoellz\WS3Y3XzJGFDS0JzIH3SUmEh\XiycnXzd4lwdg>? MV[yN|A3ODV5MB?=
MOLT4/DNR M3[5dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWO1JO69VQ>? M2O1SlQh\A>? NUTsfYM2emWmdXPld{B1cGViSVO1NOKhfmGudXWg[o9zKGSjdX7vdpVjcWOrbjDz[Y5{cXSrdnn0fS=> M3nXPVI{ODZyNUew
Jurkat/DOX MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHm2dIg2KM7:TR?= MnG5OEBl NHLpWnRz\WS3Y3XzJJRp\SCLQ{WwxsB3[Wy3ZTDmc5Ih\GG3bn;yeYJq[2mwIIPlcpNqfGm4aYT5 M{fTWlI{ODZyNUew
ccRCC  NUO2SpBiSXCxcITvd4l{KEG|c3H5 NV;FWJd5OC5yMT2xNO69VQ>? MWS3NkBp MX3EUXNQ NIPmfXFp[XNibXnubY1idCCnZn\lZ5Qhd25iY3XscEBxem:uaX\ldoF1cW:w NUL6bndOOjJ6Mk[0Olc>
TNBC  M1TqSGFxd3C2b4Ppd{BCe3OjeR?= NYnHUGM4OC5yMT2xNO69VQ>? NFfTRYk4OiCq MnTFSG1UVw>? NGjWc2pp[XNibXnubY1idCCnZn\lZ5Qhd25iY3XscEBxem:uaX\ldoF1cW:w NEfJfFkzOjh{NkS2Oy=>
A498 M{TEXmFxd3C2b4Ppd{BCe3OjeR?= MmD2NE4xOS1zMN88US=> M{m2S|czKGh? MnLESG1UVw>? MVvpcoR2[2W|IIP5coVz\2m|dHnjJJJme3CxboPld:Khf2m2aDDyc41q\GWyc3nu NX3zO3BnOjJ6Mk[0Olc>
KIJ265T NF;WZ3JCeG:ydH;zbZMhSXO|YYm= NFjsSFAxNjBzLUGw{txO M4PTWVczKGh? NIrnXoZFVVOR NWjzZ4x7cW6mdXPld{B{gW6ncnfpd5Rq[yC{ZYPwc45{\XQEoIfpeIghem:vaXTldJNqdg>? MVyyNlgzPjR4Nx?=
MDA-231 M{PXdmFxd3C2b4Ppd{BCe3OjeR?= MUGwMlAyNTFyzszN MVq3NkBp NEfDbpZFVVOR Mn7JbY5lfWOnczDzfY5memerc4TpZ{Bz\XOyb37z[ZPDqHerdHigdo9ucWSncIPpci=> NFrqbWkzOjh{NkS2Oy=>
BT-20 MoDPRZBweHSxc3nzJGF{e2G7 NI[1d3cxNjBzLUGw{txO NYHiUnNkPzJiaB?= MoPNSG1UVw>? MVrpcoR2[2W|IIP5coVz\2m|dHnjJJJme3CxboPld:Khf2m2aDDyc41q\GWyc3nu MVmyNlgzPjR4Nx?=
U937 NWW3V45yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkT2OU0zOCEQvF2= MWiyOE81QC95MjDo NXTwbY54cW6mdXPld{BiKGSnY4LlZZNmKGmwIHPlcIwhfmmjYnnsbZR6KGmwIHGgZ49v[2WwdILheIlwdi1iYX7kJJRqdWVvZHXw[Y5l\W62IH3hco5meg>? NFLw[IIzOjd4N{CyNS=>
HL60 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MonWOU0zOCEQvF2= NWPNV3hLOjRxNEivO|IhcA>? M2T0bYlv\HWlZYOgZUBl\WO{ZXHz[UBqdiClZXzsJJZq[WKrbHn0fUBqdiCjIHPvcoNmdnS{YYTpc44uKGGwZDD0bY1mNWSncHXu[IVvfCCvYX7u[ZI> NFPoN4YzOjd4N{CyNS=>
U937 NWHTUFlNSXCxcITvd4l{KEG|c3H5 MmnINVUh|ryP M3zFZ|I1NzR6L{eyJIg> Mn;ObY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? NYjiSXN3OjJ5NkewNlE>
HL60 MkjkRZBweHSxc3nzJGF{e2G7 M4XjWFE2KM7:TR?= NX3GR49ZOjRxNEivO|IhcA>? MkPDbY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? MUKyNlc3PzB{MR?=
LS411N  NGTwWIVCeG:ydH;zbZMhSXO|YYm= M{TMWVAvPSEQvF2= MnnpO|IhcA>? M3LUfYlv[3KnYYPld{BH[XNibWLORUBt\X[nbB?= NGK2bFYzOjR4MU[5OS=>
MDA-MB-231 NUexdVR6SXCxcITvd4l{KEG|c3H5 MXWxNEDPxE1? NGrSS2o1QCCq NU\xS|BuemWmdXPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NFPXWpIzOTh6N{[5Oy=>
MCF-7  MXfBdI9xfG:|aYOgRZN{[Xl? MkjvNVAh|ryP MV20PEBp M{\QcpJm\HWlZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? M3TwdVIyQDh5Nkm3
A375 NGGyOIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVKwMlUh|ryP MY[xM|UwQCCm M4fGOIlvcGmkaYTzJJBzd2yrZnXyZZRqd25iYX7kJIlv\HWlZYOg[Iln\mW{ZX70bYF1cW:wIH;mJI1mdGGwb33hJINmdGy| Mn2wNlE4QTZ4MkK=
SKMEL1 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M32x[lAvPSEQvF2= M3H5U|EwPS96IHS= M2[3dIlvcGmkaYTzJJBzd2yrZnXyZZRqd25iYX7kJIlv\HWlZYOg[Iln\mW{ZX70bYF1cW:wIH;mJI1mdGGwb33hJINmdGy| NEXmZmEzOTd7Nk[yNi=>
SKMEL3 NWHFdFZDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnvmNE42KM7:TR?= NWnFcJBKOS93L{ig[C=> Mn;WbY5pcWKrdIOgdJJwdGmoZYLheIlwdiCjbnSgbY5lfWOnczDkbYZn\XKnboTpZZRqd25ib3[gcYVt[W6xbXGgZ4VtdHN? M3:wZlIyPzl4NkKy
SKMEL28 NYfhXY53T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmXuNE42KM7:TR?= NIHlb2gyNzVxODDk MWnpcohq[mm2czDwdo9tcW[ncnH0bY9vKGGwZDDpcoR2[2W|IHTp[oZmemWwdHnheIlwdiCxZjDt[Yxidm:vYTDj[Yxtew>? M3:3SVIyPzl4NkKy
MeWo M1j0UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXKwMlUh|ryP NWrWfZlWOS93L{ig[C=> MVvpcohq[mm2czDwdo9tcW[ncnH0bY9vKGGwZDDpcoR2[2W|IHTp[oZmemWwdHnheIlwdiCxZjDt[Yxidm:vYTDj[Yxtew>? NEXnXYkzOTd7Nk[yNi=>
B16 NIjqTZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M37SPVAvPSEQvF2= M2nt[lEwPS96IHS= NXjNVFJmcW6qaXLpeJMheHKxbHnm[ZJifGmxbjDhcoQhcW6mdXPld{BlcW[oZYLlcpRq[XSrb36gc4YhdWWuYX7vcYEh[2WubIO= NWTmSnJKOjF5OU[2NlI>
Ly 1 NV;a[FgxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXqyOEBp MniyTWM2OD15LkOg{txO MnnQNlE4PzJyNEm=
Ly 7 NV:1PI1ET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFX1[WIzPCCq M1j4VWlEPTB;MUCuO{DPxE1? NGn6SHAzOTd5MkC0PS=>
Su-DHL6 NXvDPWUxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NInCPGUzPCCq MWHJR|Ux97zgMkCg{txO MYmyNVc4OjB2OR?=
Ly 10 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHLpfWQzPCCq M3XDfmlEPTExvK6yNEDPxE1? NUm4R3RKOjF5N{KwOFk>
RIVA MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmC5NlQhcA>? NEnm[HdKSzVy78{eNlAh|ryP MWeyNVc4OjB2OR?=
Su-DHL2 Moq1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUL6empMOjRiaB?= NV3vUoxVUUN3MP-8olIxKM7:TR?= NEj6OXozOTd5MkC0PS=>
Ly 1 M3WwW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXHNPXhvPDhiaB?= NVPxepNUUUN3ME2wMlM1KM7:TR?= M1ixeVIyPzd{MES5
Ly 7 MkS0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlXIOFghcA>? NHLBSpFKSzVyPUCuNFI2KM7:TR?= MnjQNlE4PzJyNEm=
Su-DHL6 NVrFWGl6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX;NN|B{PDhiaB?= NXP4OIVmUUN3MP-8olIxKM7:TR?= NX[5eoFYOjF5N{KwOFk>
Ly 10 MkPjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEfKS|M1QCCq MXLJR|UxRTFwODFOwG0> M3:xcFIyPzd{MES5
RIVA Mon1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3G1fVQ5KGh? MoHZTWM2OO,:nkKwJO69VQ>? NIS4R4kzOTd5MkC0PS=>
Su-DHL2 MkLrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWLOb|NoPDhiaB?= MoS3TWM2OD1zNz60JO69VQ>? MnfyNlE4PzJyNEm=
Ly 1 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX;W[mxUPzJiaB?= NET1[YhKSzVyPUCuNFEh|ryP MWqyNVc4OjB2OR?=
Ly 7 Mn\PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWe3NkBp MUTJR|UxRTBwMEG4JO69VQ>? M2O3WVIyPzd{MES5
Su-DHL6 NGi3XmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUPRWGIyPzJiaB?= M4fjfGlEPTB;MT62JO69VQ>? NW\4bIM5OjF5N{KwOFk>
Ly 10 NXP1R|dGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFztNYw4OiCq MVPJR|UxRTFwMjFOwG0> Mn62NlE4PzJyNEm=
RIVA NH7CTZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH\nVHo4OiCq Ml76TWM2OO,:nkKwJO69VQ>? MWeyNVc4OjB2OR?=
Su-DHL2 M3vDfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NILXN4k4OiCq M{j2U2lEPTB;MUGuNkDPxE1? NIq1ZVYzOTd5MkC0PS=>

... Click to View More Cell Line Experimental Data

体内研究 Decitabine 按2.5 mg/kg 剂量作用于ALK+ KARPAS-299小鼠移植瘤模型,促进凋亡,且降低肿瘤细胞增殖,也导致肿瘤抑制基因p16INK4A的去甲基化。 [2]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:[1]
+ 展开

DNA合成检测 :

通过测定放射性胸甘摄入到DNA的情况而测定DNA合成比率。HL-60 和KG1a 细胞悬浮在6孔(直径为35 mm )盘中,孔中为含10%胎牛血清的2 mL RPMI 培养基中,然后与不同浓度相应药物温育48小时 (药物同时加入)。48小时时, 每孔加入0.5 μCi [3H] 胸甘(6.7 Ci/mmol),再温育24小时。细胞置于GF/C玻璃纤维过滤器(直径为2.4 cm)中,使用冷 0.9% NaCl, 5% 冷三氯乙酸和乙醇清洗。烘干含DNA的过滤器,置于EcoLite闪烁液(ICN)中,使用 Beckman LS 6000IC 闪烁计数器测量放射性。通过剂量-反应曲线计算IC50值。
细胞实验:[1]
+ 展开
  • Cell lines: HL-60 和 KG1a
  • Concentrations: 0 到100 ng/mL
  • Incubation Time: 96 小时
  • Method: 生长抑制实验中,指数生长期细胞接种在5 ml培养基中。向培养基中同时加入不同浓度Decitabine。在指定时间,使用模型 ZM Coulter 计数器对细胞进行计数。根据药物处理的白血病细胞的生长曲线,测定IC50值。
    (Only for Reference)
动物实验:[2]
+ 展开
  • Animal Models: KARPAS-299 人类细胞皮下接种到小鼠的左右两侧。
  • Formulation: Decitabine 溶于无菌PBS
  • Dosages: ≤2.5 mg/kg
  • Administration: 腹腔注射
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 45 mg/mL (197.18 mM)
Water 10 mg/mL (43.81 mM)
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
water
10mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 228.21
化学式

C8H12N4O4

CAS号 2353-33-5
稳定性 powder
in solvent
别名 Deoxycytidine

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03017131 Recruiting Recurrent Fallopian Tube Carcinoma|Recurrent Ovarian Carcinoma|Recurrent Primary Peritoneal Carcinoma Roswell Park Cancer Institute|National Cancer Institute (NCI) December 8 2017 Phase 1
NCT03021395 Recruiting AML Institute of Hematology & Blood Diseases Hospital February 8 2017 Phase 1|Phase 2
NCT03226418 Recruiting Adult Acute Myeloid Leukemia|Secondary Acute Myeloid Leukemia|Therapy-Related Acute Myeloid Leukemia University of Nebraska|National Cancer Institute (NCI) July 7 2017 Phase 2
NCT02839694 Withdrawn Neoplasm Metastasis|Sarcoma|Neoplasms Germ Cell and Embryonal|Melanoma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) July 7 2016 Phase 1
NCT02203773 Active not recruiting Acute Myelogenous Leukemia|Myelogenous Leukemia|Treatment Naive AML AbbVie|Genentech Inc. July 7 2015 Phase 1|Phase 2
NCT03066648 Recruiting Leukemia|Leukemia Myeloid|Leukemia Myeloid Acute|Myelodysplastic Syndromes|Preleukemia|Bone Marrow Diseases|Hematologic Diseases Novartis Pharmaceuticals|Novartis July 6 2017 Phase 1

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1:

    Is S1200 a racemic mixture or a monomer?

  • 回答:

    S1200 is R form

DNA Methyltransferase Signaling Pathway Map

Tags: 购买Decitabine | Decitabine供应商 | 采购Decitabine | Decitabine价格 | Decitabine生产 | 订购Decitabine | Decitabine代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID